eli lilly glp-1 analog says its experimental pill better than Novo's Rybelsus in diabetes study Eli Lilly Q1 Earnings Review:

It feels like something out of Vanilla Sky or Gattaca

This variability means compounded tirzepatide may not produce the same results documented in Zepbound's trials, so you cannot use Zepbound's clinical evidence to predict outcomes with a compounded formulation

Zepbound belongs to a class of medications known as dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists

45 DjankpaF

Biochemistry and Biophysics Reports , 31 , 101324

Our research shows that GLP-1 users find it significantly easier to resist cravings and control their eating, with 79% of respondents noting a decreased appetite after starting the medication